Incannex Healthcare stock tumbles after filing $100M offering
Investing.com -- Slovenian pharmaceutical company Krka reported a 6% increase in revenue to €1,048.5 million for the first half of 2025, driven by growth across all product and service groups.
The company’s net profit rose 11% year-over-year to €246.7 million, compared to €221.6 million in the same period last year.
Operating profit (EBIT) increased 8% to €257 million, with the EBIT margin improving slightly to 24.5% from 24.1% in the first half of 2024. EBITDA margin remained stable at 28.9%.
Krka saw particularly strong performance in Eastern Europe, which accounts for 35.4% of total sales, with revenue growing 11% in this region compared to the same period last year.
Capital expenditure for the first half reached €40.9 million, representing approximately 27% of the €150 million planned for the full year. The company said the capital spending is aimed at upgrading production capacities and infrastructure.
Krka reiterated its full-year 2025 guidance, expecting revenue to exceed €2 billion and net income to reach approximately €365 million. The company maintained its capital expenditure target of around €150 million for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.